9/1 - You (nar)CAN Save a Life
The opioid epidemic has reached every corner of the country, but so do efforts to curb the impact on communities.
Meet UTMB’s Center for Addiction Sciences and Therapeutics at the Market and:
Ask/speak to local experts & scientists studying at addiction the neurobiological level.
Learn how to recognize and respond to an opioid overdose!
Get FREE Narcan (opioid overdose reversal medication) nasal spray. (Limited Supply)
Dates:
September 1, 2024
9:00 AM - 12:00 PM
About Center for Addiction Research at the University of Texas Medical Branch
The Center for Addiction Research (CAR) was established in January 2004 as an institutional center of excellence at UTMB and provides the infrastructure for research and education in substance use disorders (SUDs), emphasizing preclinical target discovery in the addictions. The CAR currently includes 91 faculty, 23 postdoctoral fellows, 42 predoctoral mentees, 19 scientists, and four administrative staff members and is supported institutionally to advance SUDs research, mentoring/education, and community outreach.
The MISSION of the CAR is to improve the course of chronic health disorders through new understanding of biological mechanisms and translation of these discoveries into novel therapeutics to improve the lives of people in our community, state, and world.
The VISION is to define the future of molecular therapeutics for SUDs, obesity, and related chronic CNS disorders. The CAR has built strengths in target-based discovery, disease-specific knowledge, and specialized core technologies to amplify these efforts. We have partnerships with scientists, centers, and departments centrally engaged in the translational research areas of interest at UTMB and we continue to build bridges for new translational research initiatives. Ongoing studies focus on the neurobiology of dopamine, serotonin and amino acid systems, mechanisms of action of psychostimulants and analgesics, fetal exposure to medications during pregnancy, HIV/AIDS-associated neuropathology, and target and drug discovery.